Oncology Venture gets option to in-license European rights to IXEMPRA
By Nikita Chaurasia  Date: 2019-04-05

Oncology Venture gets option to in-license European rights to IXEMPRA

Oncology Venture has reportedly gained an exclusive option to in-license the European rights to IXEMPRA® (ixabepilone) from the pharma company R-Pharm U.S., LLC. As per trusted sources, the aforesaid firm acquired global rights to IXEMPRA® from Bristol-Myers Squibb in July 2015 and the drug is permitted in the USA for the treatment of breast cancer.

Oncology Venture will assess ixabepilone along with its drug-specific DRP® companion diagnostic to obtain market approval in Europe.

According to a press release by Oncology Venture, the company has assessed the capacity of its DRP® companion diagnostic to detect which patients will most likely benefit from ixabepilone, depending on previous treatment results and information on tumor gene published by BMS in the scientific literature. The study specifies that patients profiting from Ixabepilone can be recognized through ixabepilone-specific DRP® companion diagnostic. Moreover, the company is certain that it will prevail in its quest to gain EMA approval in order to market ixabepilone across Europe to treat individuals with metastatic breast cancer.

As per the agreement, IXEMPRA® (ixabepilone) will undergo clinical trials in Europe with metastatic breast cancer patients, where the drug will be evaluated by Oncology Venture together with its DRP® companion diagnostic. If the trials unveil convincing results, Oncology Venture will have the option to in-license the commercial rights for IXEMPRA® in the European market. The extended pipeline is not anticipated to surge Oncology Venture’s cost base as the clinical development of ixabepilone will be funded via a special purpose vehicle/joint venture to be open to interested investors while the program will be controlled by Oncology Venture. 

For the record, ixabepilone was initially developed by Bristol-Myers Squibb and was permitted for the treatment of metastatic breast cancer by the US FDA in 2007 but failed to receive approval from the European Medicines Agency for the drug to be marketed in Europe. Currently, the product is marketed by R-Pharm in the USA, as well as in Switzerland, Lichtenstein and some parts of South America, reported sources.

About Author

Nikita Chaurasia    

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

Abry adds HealthEZ to its pool of healthcare service investments
Abry adds HealthEZ to its pool of healthcare service investments
By Nikita Chaurasia

Abry Partners, one of the most successful private equity investment firms in North America, has reportedly made it to the headlines for acquiring majority stake in a Minnesota-based third-party administrator of self-funded medical plans, HealthEZ. T...

Welltel acquires Kildare-based secure IT & cloud service provider Novi
Welltel acquires Kildare-based secure IT & cloud service provider Novi
By Nikita Chaurasia

Ireland-based end-to-end communication services provider, Welltel has recently announced the acquisition of Novi, a Kildare-based IT service firm. With the said acquisition the two companies would now be able to offer an integrated suite of secure co...

Canzon to explore German market by partnering with Lykos Verde
Canzon to explore German market by partnering with Lykos Verde
By Nikita Chaurasia

Canzon, an Israeli enterprise selling CBD-based products in Europe has reportedly entered a partnership worth NIS 6 million yearly with German distribution firm Lykos Verde. Sources close to the matter stated that as per the agreement, Lykos Verde w...

Société Générale purchases Shine to expand retail banking portfolio
Société Générale purchases Shine to expand retail banking portfolio
By Nikita Chaurasia

France-based multinational investment bank Société Générale S.A. has reportedly acquired Shine, a neobank for entrepreneurs, for an undisclosed sum. According to reliable sources, the acquisition will allow the financial s...

Taiwan Mobile selects Nokia for 5G connectivity in a €400 million deal
Taiwan Mobile selects Nokia for 5G connectivity in a €400 million deal
By Nikita Chaurasia

Nokia made an announcement that the Taiwan Mobile (TWM) has chosen it as the exclusive supplier of its 5G network in a 3 year framework deal valuing around 400 million euros. As per trusted sources the initial phase of the deal which includes 5G Cor...